Literature DB >> 27438082

Treatment of pediatric cerebral radiation necrosis: a systematic review.

N Drezner1, K K Hardy2, E Wells3, G Vezina4, C Y Ho5, R J Packer3, E I Hwang6.   

Abstract

Cerebral radiation necrosis (CRN) is a toxicity of radiation therapy that can result in significant, potentially life-threatening neurologic deficits. Treatment for CRN has included surgical resection, corticosteroids, hyperbaric oxygen therapy (HBOT), and bevacizumab, but no consensus approach has been identified. We reviewed the available literature to evaluate efficacy of treatment approaches. Using methods specified in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines when possible, we conducted searches of Ovid MEDLINE, Embase and Pubmed to identify studies reporting on outcomes for children (≤21 years old) with CRN. Eligible studies from 1990 to 2014 describing central nervous system (CNS) radiation necrosis with details of both treatment and outcomes were included. Eleven studies meeting criteria were identified. Of the nine studies with total patient denominators, 37 of 806 patients developed CRN (incidence = 4.6 %). Patients received treatment courses of steroids alone (n = 13), steroids with bevacizumab (n = 11) or HBOT (n = 12). Patients who failed to respond to steroids were more likely to be older than steroid-responsive patients (p = 0.009). With the exception of steroid-related adverse events, there was only one report of an adverse event (brainstem stroke) potentially attributable to intervention (bevacizumab). Those who received proton beam RT were both younger (p = 0.001) and had a shorter time to development of CRN (p = 0.079). The most common treatment following steroid initiation was addition of bevacizumab or HBOT, with good success and minimal toxicity. However, randomized controlled trials are needed to establish a definitive treatment algorithm that can be applied to children affected by CRN.

Entities:  

Keywords:  Brain; Late effects; Necrosis; Pediatric; Radiation

Mesh:

Substances:

Year:  2016        PMID: 27438082     DOI: 10.1007/s11060-016-2219-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Magnetic resonance spectroscopy (MRS) in the evaluation of pediatric brain tumors, Part II: Clinical analysis.

Authors:  S E Byrd; T Tomita; P S Palka; C F Darling; J P Norfray; J Fan
Journal:  J Natl Med Assoc       Date:  1996-11       Impact factor: 1.798

2.  Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas.

Authors:  Kimberly A Foster; William J Ares; Ian F Pollack; Regina I Jakacki
Journal:  Pediatr Blood Cancer       Date:  2014-11-08       Impact factor: 3.167

3.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Authors:  Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

4.  Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases.

Authors:  Motomasa Furuse; Shinji Kawabata; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  J Neurooncol       Date:  2010-08-07       Impact factor: 4.130

5.  Treatment of radiation-induced nervous system injury with heparin and warfarin.

Authors:  M J Glantz; P C Burger; A H Friedman; R A Radtke; E W Massey; S C Schold
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

6.  Brain irradiation: effects on normal brain parenchyma and radiation injury.

Authors:  Pia C Sundgren; Yue Cao
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

7.  Adverse radiation effects after radiosurgery may benefit from oral vitamin E and pentoxifylline therapy: a pilot study.

Authors:  Richard Williamson; Douglas Kondziolka; Hilal Kanaan; L Dade Lunsford; John C Flickinger
Journal:  Stereotact Funct Neurosurg       Date:  2008-10-16       Impact factor: 1.875

8.  Hyperbaric oxygen therapy for radiation-induced brain injury in children.

Authors:  P J Chuba; P Aronin; K Bhambhani; M Eichenhorn; L Zamarano; P Cianci; M Muhlbauer; A T Porter; J Fontanesi
Journal:  Cancer       Date:  1997-11-15       Impact factor: 6.860

9.  Incidence and clinical course of radionecrosis in children with brain tumors. A 20-year longitudinal observational study.

Authors:  V Strenger; H Lackner; R Mayer; P Sminia; P Sovinz; M Mokry; A Pilhatsch; M Benesch; W Schwinger; M Seidel; D Sperl; S Schmidt; C Urban
Journal:  Strahlenther Onkol       Date:  2013-08-22       Impact factor: 3.621

10.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.

Authors:  David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart
Journal:  Syst Rev       Date:  2015-01-01
View more
  8 in total

1.  Bevacizumab in the treatment of radiation injury for children with central nervous system tumors.

Authors:  Nathan A Dahl; Arthur K Liu; Nicholas K Foreman; Melissa Widener; Laura Z Fenton; Margaret E Macy
Journal:  Childs Nerv Syst       Date:  2019-07-31       Impact factor: 1.475

2.  Treatment of radiation-induced myelopathy with bevacizumab.

Authors:  G Cañedo; I Solis; C González-San Segundo; L Madero; A Lassaletta
Journal:  Clin Transl Oncol       Date:  2019-09-21       Impact factor: 3.405

3.  Does a Bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma? A systematic review.

Authors:  Mia Evans; Ria Gill; Kim S Bull
Journal:  Neurooncol Adv       Date:  2022-06-24

4.  Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.

Authors:  Jessica L Narloch; S Harrison Farber; Sarah Sammons; Frances McSherry; James E Herndon; Jenny K Hoang; Fang-Fang Yin; John H Sampson; Peter E Fecci; Kimberly L Blackwell; John P Kirkpatrick; Grace J Kim
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

Review 5.  Brain metastases: An update on the multi-disciplinary approach of clinical management.

Authors:  D K Mitchell; H J Kwon; P A Kubica; W X Huff; R O'Regan; M Dey
Journal:  Neurochirurgie       Date:  2021-04-14       Impact factor: 1.553

Review 6.  Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.

Authors:  Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.575

7.  Neuro-oncologists have spoken - the role of bevacizumab in the inpatient setting. A clinical and economic conundrum.

Authors:  Akanksha Sharma; Justin Low; Maciej M Mrugala
Journal:  Neurooncol Pract       Date:  2018-04-19

8.  Bevacizumab for pediatric radiation necrosis.

Authors:  Lorena V Baroni; Daniel Alderete; Palma Solano-Paez; Carlos Rugilo; Candela Freytes; Suzanne Laughlin; Adriana Fonseca; Ute Bartels; Uri Tabori; Eric Bouffet; Annie Huang; Normand Laperriere; Derek S Tsang; David Sumerauer; Martin Kyncl; Barbora Ondrová; Vajiranee S Malalasekera; Jordan R Hansford; Michal Zápotocký; Vijay Ramaswamy
Journal:  Neurooncol Pract       Date:  2020-01-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.